Suzhou Raymon Pharmaceuticals Co. Ltd. has identified nitric oxide (NO) donor-containing compounds reported to be useful for the treatment of glaucoma, age-related macular degeneration, diabetic retinopathy, cataract, uveitis, keratitis and ocular hypertension.
Novo Nordisk A/S has disclosed GLP-1 polypeptide analogues acting as glucagon-like peptide-1 receptor (GLP-1R) agonists. As such, they are reported to be useful for the treatment of obesity and diabetes.
Gwangju Institute of Science & Technology, National Cancer Center of Korea and Seoul National University have jointly divulged new PreS1 (hepatitis B virus, HBV) derivatives for the treatment of HBV infection.
The University of Kansas has synthesized TNF-α (ARE sequence)/ELAV-like protein 1 (HuR) interaction inhibitors. They are reported to be useful for the treatment of cancer, kidney fibrosis, liver fibrosis, pulmonary fibrosis and myocardial fibrosis.
A University of Sydney patent details new cyclic peptides acting as coagulation factor XIa inhibitors reported to be useful for the treatment of thrombosis.
Hetero Labs Ltd. has patented benzimidazole compounds acting as EGFR (HER1; erbB1) and its mutant inhibitors. They are reported to be useful for the treatment of cancer.
Helmholtz Zentrum Fur Infektionsforschung GmbH has reported argyrin derivatives designed for potential use for the treatment of Neisseria gonorrhoeae and Clostridioides difficile infections.
U.S. Department of Health and Human Services (HHS) has discovered dopamine D2 receptor antagonists potentially useful for the treatment of Tourette disease, bipolar disorder, tardive dyskinesia, Huntington’s disease, schizophrenia, depression, postoperative nausea and vomiting and gastroesophageal reflux disease.
Avicenna Biosciences Inc. has reported Rho kinase (ROCK) inhibitors described as potentially useful for the treatment of cancer, fibrosis, neurodegeneration, overactive bladder, scleroderma, diabetic retinopathy, traumatic brain injury and renal disorders, among others.
RSS